Journal article
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
- Abstract:
-
Background: The phase 3 FUTURE 5 trial (NCT02404350) showed the clinical and radiographical efficacy of secukinumab in patients with psoriatic arthritis. This analysis aimed to assess the effect of secukinumab on patient-reported outcomes (PROs).
Methods: FUTURE 5 was a phase 3, multicentre, parallel-group randomised trial in which patients who were 18 years old or older, met the classification criteria for psoriatic arthritis at screening, and had...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 888.6KB, Terms of use)
-
- Publisher copy:
- 10.1016/S2665-9913(21)00354-4
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Rheumatology More from this journal
- Volume:
- 4
- Issue:
- 3
- Pages:
- E208-E219
- Publication date:
- 2022-02-01
- Acceptance date:
- 2021-10-25
- DOI:
- EISSN:
-
2665-9913
- Language:
-
English
- Keywords:
- Pubs id:
-
1215478
- Local pid:
-
pubs:1215478
- Deposit date:
-
2021-12-02
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2021
- Rights statement:
- © 2021 Elsevier Ltd. All rights reserved.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/S2665-9913(21)00354-4
If you are the owner of this record, you can report an update to it here: Report update to this record